Martin Martinov, Ph.D.Co-Founder, CTO
Dr. Martinov has developed and refined the core proprietary technology of FAR Biotech. Dr. Martinov has provided molecular modeling services pharmaceuticals, diagnostics, and imaging IT solutions to various clients, including Eastman Kodak, Elan Pharmaceuticals, Vitae Pharmaceuticals as well as to multiple biotech start-ups. Dr. Martinov has a Ph.D. in Molecular Biophysics from Florida State University and has done post-doctoral research at Rensselaer Polytechnic Institute.
Val Angelkov, MBACo-Founder, CEO
Mr. Angelkov has 15 years of executive and business development experience roles within the alternative energy industry in the United States. Prior to co-founding FAR Biotech, Mr. Angelkov was investment professional at an alternative energy private equity group, and prior to that held commercial leadership roles at EDPR North America and Constellation Energy. Mr. holds an MBA from the University of Texas at Austin, BA from the American University in Bulgaria, and is a CFA charter holder.
Pooja Dhupkar, Ph.D.CRO Project Manager
Dr. Dhupkar manages third party CROs with respect to compound procurement and synthesis and vitro bioassay testing. Prior to joining FAR Biotech, Dr. Dhupkar was a post-doctoral researcher at MD Anderson in the field of novel immuno-therapy and chemotherapy-induced toxicity in sarcoma. , Dr. Dhupkar earned her MS in Pharmacology and Toxicology from University of Sciences in Philadelphia and her BS in Pharmaceutical Sciences from the University of Mumbai.
Lubomir Nashev, Ph.D.Research Director
Dr. Nashev holds a Ph.D. in Biochemistry and Molecular medicine from the University of Berne in Switzerland and did his four year post-doctoral training at Pharmacetrum at the University of Basle, Switzerland. Dr. Nashev gained prior bio-informatics experience at Metalife AG. Dr. Nashev is in charge of cheminformatic pre- and post-processing of molecular databases and related pharmacological models for FAR Biotech.